INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $22.80.
INMB has been the topic of a number of recent research reports. Scotiabank raised their target price on shares of INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a report on Tuesday, February 11th. RODMAN&RENSHAW upgraded INmune Bio to a "strong-buy" rating in a research note on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of INmune Bio in a report on Tuesday, January 28th. They set a "buy" rating and a $23.00 price target for the company. Finally, Maxim Group increased their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, February 13th.
Get Our Latest Report on INMB
Institutional Investors Weigh In On INmune Bio
A number of hedge funds and other institutional investors have recently modified their holdings of INMB. Raymond James Financial Inc. bought a new position in INmune Bio in the 4th quarter valued at about $2,221,000. Praetorian PR LLC increased its stake in shares of INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company's stock valued at $4,209,000 after acquiring an additional 295,800 shares during the period. Dauntless Investment Group LLC bought a new stake in INmune Bio during the fourth quarter worth approximately $896,000. Millennium Management LLC lifted its position in INmune Bio by 43.9% in the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company's stock worth $1,360,000 after purchasing an additional 88,823 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in INmune Bio by 73.3% during the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company's stock valued at $868,000 after purchasing an additional 78,600 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors.
INmune Bio Stock Down 8.3 %
Shares of INMB traded down $0.73 during midday trading on Monday, hitting $8.04. The company had a trading volume of 153,810 shares, compared to its average volume of 408,223. INmune Bio has a 52 week low of $4.32 and a 52 week high of $12.72. The company's 50 day moving average price is $7.89 and its 200 day moving average price is $6.26. The stock has a market cap of $178.26 million, a price-to-earnings ratio of -3.69 and a beta of 1.93.
About INmune Bio
(
Get Free ReportINmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Further Reading
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
